Indication for platelet transfusion in patients with haematological diseases: Less is more;Indikation zur Thrombozytentransfusion bei Hämatologischen Patienten weniger ist mehr!

Deutsche Medizinische Wochenschrift

Volumn 135, Issue 38, 2010, Pages 1877-1879

  Wandt, H ^a  

^a KLINIKUM NÜRNBERG   (Germany)

Author keywords

platelet transfusion; thrombocytopenia

Indexed keywords

HEMATOLOGIC DISEASE; HLA SYSTEM; HUMAN; NOTE; PREVENTIVE MEDICINE; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT INDICATION;

AGED; CHILD; HEMORRHAGE; HUMANS; LEUKEMIA; PLATELET COUNT; PLATELET TRANSFUSION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 77956894535     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0030-1263332     Document Type: Note

References (12)

1. Empfehlungen zur Thrombozytentransfusion: Thrombozyten Arbeitsgruppe der DGTI, GTH und DGHO. www.dgho.de/informationen/leitlinien/allgemeines- therapieverfahren/
2. Gaydos L A., Freirecht E J., Mantel N. The quantitative relation between platelet count and hemorrhage in patients with acute leukemia. N Engl J Med 1962 266 905-909
3. Gmr J, Burger J, Schanz U et al. Safety of stringent prophylactis platelet transfusion policy for patients with acute leukemia. Lancet 1991 338 1223-1226
4. Heddle N M., Cook R J., Tinmouth A et al. A randomized controlled trial comparing standard- and low-dose strategies for transfusion of platelets (STOP) to patients with thrombocytopenia. Blood 2009 113 1564-1573
5. Leucocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The Trail to Reduce Alloimmunization to Platelets Study Group. N Engl J Med 1997 337 1861-1869
6. Querschnitts-Leitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten; 2 Thrombozytenkonzentrate. Kln Deutscher rzteverlag 2009 33-55
7. Sagmeister M, Oec L, Gmr J. A restrictive platelet transfusion policy allowing long-term support of outpatients with severe aplastic anemia. Blood 1999 93 3124-3126
8. Slichter S J., Davis K, Enright H et al. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood 2005 105 4106-4114
9. Slichter S J., Kaufmann R M., Assmann S F. et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med 2010 362 600-13
10. Schrezenmeier H, Seifried E. Buffy-coat-derived pooled platelet concentrates and apheresis platelet concentrates: which product type should be preferred? Vox Sang 2010; Jan 4. Epub
11. Wandt H, Frank M, Ehninger G et al. Safety and cost effectiveness of a 10x109/l trigger for prophylactic platelet transfusion compared with the traditional 20x109/l trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia. Blood 1998 91 3601-3606
12. Wandt H, Schaefer-Eckart K, Frank M et al. A therapeutic platelet transfusion strategy is safe and feasible in patients after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2006 37 387-392